Study of Apatinib Combined With TACE in Advance Hepatocellular Carcinoma

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT03398122
Status
Unknown

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 70 Years
Healthy Volunteers
Accepted

Interventions

  • TACE — PROCEDURE
    epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.
  • Apatinib — DRUG
    a molecular targeted anti-tumor drugs,small molecule vascular endothelial growth factor receptor 2 inhibitor

Study Details

the purpose of this study is to evaluate the efficacy and safety of aptinib in patients with advanced HCC

Key Dates

Start date
Nov 14, 2017
Status verified
Nov 2017
Primary completion
Oct 1, 2018
Completion
Apr 1, 2019

Study Design

Enrollment
248 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Apatinib combined with TACE
    patients received Aptinib, 250 mg daily after TACE treatment, for 4-6 weeks
  • Placebo Comparator: chemoemtranscatherer arterial bolization
    epirubicin 30-60mg was injected into the blood supply artery of the tumor ,Embolization was subsequently performed with granules of gelatin sponge particles.

Primary Outcome Measure

PFS [ Time Frame: one and a half year ]

Central Contacts

Related Studies